Table 2 Results of the meta-analysis of the secondary outcomes.

From: T-cell specific antibody induction versus corticosteroid induction immunosuppression for liver transplant recipients: a meta-analysis

Outcomes

Studies

Antibody

Steroid

Effect size [95% CI]*

P-value

I2

Mortality4,5,18,19,20,21,22,23,24,25

10

879

804

0.94 [0.72, 1.24]

0.67

29%

Graft failure4,5,18,19,20,21,22,23,24,25

10

879

804

1.07 [0.84, 1.36]

0.58

25%

Acute rejection requiring treatment4,5,20,21,22,23,24

7

693

611

0.90 [0.73, 1.11]

0.31

0%

Corticosteroid resistant rejection4,5,21,22

4

506

503

0.64 [0.34, 1.18]

0.15

45%

Adverse events5,19,22,23

4

475

475

0.97 [0.94, 1.01]

0.13

76%

Infection4,5,21,23,24,25

6

671

587

0.88 [0.72, 1.09]

0.24

0%

CMV infection5,21,23,24,25

5

619

535

0.48 [0.33, 0.70]

0.0002

3%

HCV recurrence20,21,22,23,24,25

6

298

229

0.89 [0.80, 0.99]

0.03

0%

Malignancy5,20,21,22,23,24

6

590

582

0.80 [0.33, 1.98]

0.63

0%

PTLD5,20,21,22,23

5

485

487

1.00 [0.07, 15.38]

1.00

N/A

Total length of hospital stay (days)4,23

2

78

73

0.19 [− 3.26, 3.64]

0.91

0%

Renal failure requiring dialysis4,5,21

3

439

435

1.29 [0.57, 2.90]

0.54

0%

GFR4,21,22

3

118

144

4.77 [1.24, 8.29]

0.008

3%

Serum creatinine level (mmol/L)5,22,24

3

508

466

13.93 [7.83, 20.02]

 < 0.0001

0%

Diabetes mellitus4,5,18,19,20,21,22,23,24,25

10

857

775

0.41 [0.32, 0.54]

 < 0.0001

0%

Hyperlipidemia4,5,18,24

5

644

566

0.92 [0.71, 1.20]

0.54

70%

Serum cholesterol level (mg/dL)4,5,20

4

418

414

− 22.46 [− 28.94, − 15.98]

 < 0.0001

22%

Hypertension4,5,18,19,20,21

6

566

563

0.71 [0.55, 0.90]

0.005

35%

  1. *The data are presented as mean difference or risk ratio with its 95% confidence interval (CI).
  2. CMV = cytomegalovirus; HCV = hepatitis C virus; PTLD = post-transplant lymphoproliferative disorder; GFR = glomerular filtration rate; N/A = not available.
Back to article page